secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2026-05-04T23:59:59+00:00
Accession:  0001104659-26-054942
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q1 revenue $47.8M (+16% YoY); raises FY2026 guidance to $192-196M
--------------------------------------------------------------------------

- Q1 revenue $47.8M (+16% YoY); commercial CGT revenue $9.1M (+26%).
- Life Sciences Services revenue $26.9M (+18%); BioStorage/BioServices up 21%.
- Supported 766 global clinical trials (91 Phase 3) and 21 commercial CGTs as of March 31.
- FY2026 revenue guidance raised to $192M-$196M versus prior outlook.
- Four BLA/MAA filings in Q1; Rocket Pharma FDA approval for KRESLADI gene therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465926054942/0001104659-26-054942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465926054942/tm2613494d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-054942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer